期刊文献+

炎性细胞因子作为淋巴瘤生物标志物和分子靶点的研究进展 被引量:1

Progress of inflammatory cytokines as lymphoma biomarkers and molecular targets
原文传递
导出
摘要 炎症反应存在于大多数疾病的发展过程中,近年来,肿瘤相关炎症反应在肿瘤微环境中的作用逐渐受到重视.炎症反应可促进局部淋巴瘤发生,同时淋巴瘤细胞的生长、增殖亦依赖于炎性肿瘤微环境,炎症反应在淋巴瘤的发生、发展及治疗过程中具有重要作用.炎性细胞因子是炎症介质的主要类别,其表达水平反映机体的炎症反应状态,具有作为淋巴瘤生物标志物和分子靶点的潜力. The inflammatory response is involved in the development of most diseases. In recent years, tumor associated inflammatory response in tumor microenvironment has been paid more attention. Inflammation promotes the progress of lymphoma, and the growth and proliferation of lymphoma cells also depend on the inflammatory tumor microenvironment. Inflammatory response plays an important role in the development and treatment of lymphoma. Inflammatory cytokines are main types of inflammatory mediators, their expression levels reflect the inflammatory response state of the body, and have potential to be biomarkers and molecular targets of lymphoma.
作者 王艳荣 韩晓红 石远凯 Wang Yanrong;Han Xiaohong;Shi Yuankai(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Department of Clinical Laboratory,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100021,China)
出处 《白血病.淋巴瘤》 CAS 2019年第8期501-505,共5页 Journal of Leukemia & Lymphoma
关键词 系统性炎症反应综合征 淋巴瘤 肿瘤标记 生物学 分子靶向治疗 Systemic inflammatory response syndrome Lymphoma Tumor markers,biological Molecular targeted therapy
  • 相关文献

参考文献2

二级参考文献40

  • 1张乃红,陈玉梅,邹尧,刘天峰,竺晓凡.急性杂合性白血病伴慢性乙肝病毒携带1例报告[J].中国小儿血液,2005,10(1):35-36. 被引量:1
  • 2Morris J, Eddleston A, Crook T. Viral infection and cancer[J]. Lancet,1995, 346: 754-758.
  • 3Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell nonHodgkin's lymphomas:an Italian multicenter case- control study [J].Blood, 2003, 102: 996-999.
  • 4Hausfater P, Cacoub P, Sterkers Y, et al. Hepatitis C virus infection an lymphoproliferative diseases:prospective study on 1576 patients in France[J]. Am J Hematol, 2001, 67: 168-171.
  • 5Ellis M, Rathaus M, Amiel A, et al. Monoclonal lymphocytes proliferation and bcl-2 rearrangement in essential mixed cryoglobulinemia[J].Eur J Clin Invest, 1995, 25: 833-837.
  • 6Zuckerman E, Zuckerman T, Sahar D, et al. bcl-2 and immunoglobulin gene rearrangement in patients with HCV infection[J]. Br J Hematol, 2001, 112: 364-369.
  • 7Ivnovski M, Silversti F, Pozzato G, et al. Somatic mutation,clonal diversity, and preferential expression of the VH51pl/Vlkv325 immunocytomas[J]. Blood, 1998, 91: 2433-2442.
  • 8Zuckerman E, Zuckerman T. Hepatitis C and B-cell lymphoma:the hemato-hepatologist linkage[J]. Blood Reviews, 2002, 16:119-125.
  • 9Ray R B, Meyer K, Ray R, et al. Suppression of apoptotic cell death by hepatitis C core protein[J]. Vorology, 1996, 226: 176-182.
  • 10Levy S, Todd S C, Maecker H T, et al. CD81(TAPA- 1):a molecule involved in signal transduction and cell adhesion in the immune system [J]. Annu Rev lmmunol, 1998, 16: 89-106.

共引文献3

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部